1. DOP82 Biological Treatment Cycles in Crohn's Disease. (30th January 2023) Authors: Noor, N; Sousa, P; Bettenworth, D; Gomollon, F; Lobaton, T; Bossuyt, P; Casanova, M J; Ding, N; Dragoni, G; Furfaro, F; van Rheenen, P; Chaparro, M; Gisbert, J; Louis, E; Papamichael, K Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA. (30th January 2023) Authors: Gargallo-Puyuelo, C; Ricard, E; Iborra, M; Iglesias-Flores, E; Vera Mendoza, I; De Francisco García, R; Calafat Sard, M; Minguez, M; Lopez- San Roman, A; Taxonera, C; Guardiola, J; Barrio, J; Laredo, V; De Castro, L; Gisbert, J; García-Lopez, S; García Planella, E; Martín Arranz, D; Calvet, X; Me... Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease. (27th May 2021) Authors: Dignass, A; Gisbert, J; Freudensprung, U; Addison, J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P790 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU. (25th January 2019) Authors: Chaparro, M; Barreiro-de Acosta, M; Benítez, J; Cabriada, J; Casanova, M; Ceballos, D; Esteve, M; Fernández, H; Ginard, D; Gomollón, F; Lorente, R; Nos, P; Riestra, S; Rivero, M; Robledo, P; Rodríguez, C; Sicilia, B; Torrella, E; Garre, A; Rodríguez-Artalejo, F Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PTH-070 A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumour Necrosis Factor Antagonists. (17th August 2016) Authors: Lindsay, J; Gisbert, J; Mody, R; Peyrin-Biroulet, L; Armuzzi, A; Bokemeyer, B; Nguyen, G; Siebenaler, J; Åkerborg, Ö; Smyth, M; Rathmell, A Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PTH-071 Indicators of Suboptimal Therapy Among Crohn's Disease Patients Treated with Tumour Necrosis Factor Antagonists: Results from A Multi-National Study. (17th August 2016) Authors: Armuzzi, A; Lindsay, J; Mody, R; Bokemeyer, B; Gisbert, J; Peyrin-Biroulet, L; Nguyen, G; Siebenaler, J; Åkerborg, Ö; Smyth, M; Rathmell, A Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗